ERBB2 and neoplasm: In this work, we made the next step in our anti-HER2/neu T Cell Receptor analysis journey by employing a tumor cytotoxicity assay, single-cell RNA sequencing, bulk secretomics, and in vivo analysis of anti-HER2/neu TCR T Cells in a mouse model.